FDA to add warning to Onglyza label warning of greatly increased risk of heart failure

Page Changed: DPP-4 Inhibitors: Januvia, Onglyza, Trajenta, Combiglyze, Janumet, and Jentadueto

Added text:

In April of 2015, the data was made public that the SAVOR study showed that people taking Onglyza were 27% more likely to be hospitalized for heart failure. As a result, the FDA decided to add warning information about heart failure to the Onglyza label. (Details HERE.) However, few doctors keep up with changes to the labels of the drugs they prescribe. And as the FDA still considers this to be an acceptable drug, it will continue to be prescribed. This kind of FDA response is in line with its policy of putting the interests drug companies above those of drug users.